Ebenbuild Aims to Provide Clinicians with personalized Digital Twins of the Human Lung Solutions Home Blog Solutions Ebenbuild Aims to Provide Clinicians with personalized Digital Twins of the Human Lung 23/03/2022 Healthcare technology provider Ebenbuild has launched a research program to increase the odds of survival and recovery of those needing artificial ventilation due to acute respiratory distress syndrome. By providing doctors and nurses with an assessment of a patient’s lung condition, Ebenbuild aims to improve the quality and outcome of treatment for patients. Using the Intel Distribution for OpenVINO toolkit and OneAPI, Ebenbuild’s developers optimized pre- trained artificial intelligence inference models to run on Intel hardware, accelerating performance of the computer vision cluster. For fast data processing and visualization in the simulation cluster, Ebenbuild used the Intel Math Kernel Library and Intel C++ Compiler to optimize its application to run on Intel Xeon Scalable processors. Confidential Computing, powered by Intel Software Guard Extensions, enables Ebenbuild to process data from multiple sources and transfer it to the cloud without exposing it, even to the cloud administrators. “Confidential Computing, running on Intel Software Guard Extensions, allows us to reassure healthcare providers that the privacy, confidentiality, and integrity of sensitive patient data is maintained.“ Dr. Kei W. Müller, CEO and Co-Founder, Ebenbuild Read the full article: “Opening the ‘Black Box’” Source : Intel Also read 10/07/2024 Events Lumivero Virtual Conference 2024 As a sponsor, RITME is taking part on September 25 and 26 in the Virtual Conference organized by our partner Lumivero, on the theme of “Powerful Data Intelligence that impacts our world”. Read more Read more 18/06/2024 Events Review of the 1st Scientific Committee of Ritme The first session was held on May 24 at the Chateauform’ Saint-Dominique in Paris, with the aim of laying the groundwork for discussions on the evolving software sector. Read more Read more